Eli Lilly’s necitumumab wins FDA experts over (Report, Eli Lilly, JUL 9, 2015, View Source [SID:1234506193]). The committee members have weighed the positives and negatives of a drug that showed only a marginal survival advantage for patients with non-small cell lung cancer. The US FDA will now make a formal decision by the regulatory deadline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!